Introduction {#s1}
============

Perfluorinated chemicals (PFCs) have recently received attention because of their high-volume production, ubiquitous environmental presence and possible association with adverse health effects. PFCs were introduced in 1950 and have since been widely used in the manufacture of both domestic and industrial products having applications as grease-or-water repellents and protective coatings for clothes, furniture and other products, and also as constituents of floor polish, adhesives, firefighting foam and insulation of electrical wire ([@DEU350C11]).

The two PFCs made in the largest quantities in the USA were perflurooctanoic acid (PFOA) and perfluorooctane sulfonate (PFOS) ([@DEU350C5]). A replacement for PFOA was introduced recently which resulted in PFOA no longer being used in manufacturing processes and the key producer of PFOS phased out worldwide production in 2002 ([@DEU350C16]; [@DEU350C1]). Direct uses in Canada have largely been phased out ([@DEU350C24])---voluntarily, by most of the manufacturers of PFOA, and by federal regulation through the Canadian Environmental Protection Act (CEPA) for PFOS ([@DEU350C17]). Nonetheless, the production of PFOS has continued in China, and therefore, products containing its precursors may be still entering the Canadian market ([@DEU350C33]).

Although the production of several PFCs has declined during the last decade, recent national biomonitoring surveys in the USA ([@DEU350C11]) and Canada ([@DEU350C25]; [@DEU350C26]) have shown that nearly all participants were found to have low levels of PFOA, PFOS and perfluorohexane sulfonate (PFHxS) in their blood. These PFCs have also been detected in cord blood ([@DEU350C3],[@DEU350C4]) and breast milk ([@DEU350C21]). While the primary source of exposure in the general population is food ([@DEU350C45]), water is an important source in contaminated areas, for example, in communities near production facilities ([@DEU350C27]). In addition, PFCs have been detected in dust ([@DEU350C7]) and in indoor and outdoor air ([@DEU350C42]; [@DEU350C43]).

There is a concern about the potential adverse developmental and reproductive effects of PFCs due to their persistence in the environment and long serum elimination half-lives (i.e. 3.8, 5.4 and 8.5 years for PFOA, PFOS and PFHxS, respectively) ([@DEU350C38]). Evidence is emerging about the potential role of PFCs as endocrine-disrupting chemicals (EDCs). *In vitro*, some PFCs have the potential to affect estrogen-receptor and androgen-receptor transactivity ([@DEU350C31]). In rats, exposure to PFOS has shown estrous cyclicity disruption and neurotransmitter imbalance in adult females ([@DEU350C6]), decreased serum concentrations of thyroxine (T4) and triiodothyronine (T3) during pregnancy ([@DEU350C44]; [@DEU350C35]; [@DEU350C12]), and reduced total T4 levels in pups ([@DEU350C32]; [@DEU350C35]). In humans, PFOS concentrations in Inuit adults were negatively associated with thyroid-stimulating-hormone (TSH), total T3 and thyroxine-binding globulin (TBG) and positively with free T4 concentrations ([@DEU350C14]). In pregnant women, exposure to high concentrations of perfluorononanoic acid (PFNA), perfluoroundecanoic acid (PFUnDA) and perfluorododecanoic acid (PFDoDA) were associated with lower free T4 and total T4 levels ([@DEU350C47]).

Several epidemiological studies have explored the potential association between PFCs and fecundity, as measured by time-to-pregnancy (TTP). In a retrospective pregnancy-based TTP study within the Danish National Birth Cohort, [@DEU350C18] observed a strong association between higher concentrations of PFOA and PFOS and longer TTP. In a case--control study within the Norwegian Mother and Child Cohort (MoBa), [@DEU350C49] reported higher odds of subfecundity (TTP \> 12 months) at increasing concentrations of PFOA and PFOS. A recent analysis of the same MoBa cohort testing different statistical approaches replicated the association between PFOA and longer TTP ([@DEU350C15]). Nonetheless, [@DEU350C49], under the assumption of reverse causation suggested by [@DEU350C39] (i.e. parous women with longer time-to-pregnancy have higher PFCs levels because they have long interpregnancy intervals allowing re-accumulation of PFCs), found no association among nulliparous women after stratification by parity. When such stratification was used by [@DEU350C19], they found stronger associations for PFOS and PFOA in nulliparous women and for PFOA in multiparous women. In prospective couple-based cohort designs, [@DEU350C46] observed no consistent pattern between eight PFCs and TTP in a Danish cohort, and [@DEU350C9] reported just one (perfluorooctane sulfonamide, PFOSA) of the seven PFCs assessed in the LIFE Study (Michigan and Texas) associated with decreased fecundability. Why these studies have reported conflicting results on the association between PFCs and Time-to-Pregnancy remains unclear.

The aim of the present study was to evaluate the association between selected PFCs (PFOA, PFOS and PFHxS) and TTP in the Maternal-Infant Research on Environmental Chemicals (MIREC) Study, a Canadian pregnancy and birth cohort.

Methods {#s2}
=======

Population and study design {#s2a}
---------------------------

The MIREC Study was established to examine potential adverse health effects of exposure to priority environmental chemicals on pregnancy and infant health in Canada. The cohort profile of the MIREC Study was recently published ([@DEU350C3],[@DEU350C4]). Briefly, pregnant women from the general population who were attending early prenatal clinics from 10 cities across Canada between 2008 and 2011 were invited to participate, reaching a participation rate of 39%. Ethical considerations did not permit the collection of information on those who refused to participate. Among those who were ineligible to participate in MIREC, 52% were not planning on delivering in the participating hospitals, 20% were outside the required gestational age at recruitment and 14% were not willing to provide a sample of cord blood for the study. Some 2000 women were followed during each trimester of pregnancy, at delivery and in the early post-natal period. MIREC participants tended to smoke less (5.9 versus 10.5%), be older (mean 32.2 versus 29.4 years) and have a higher education (62.3 versus 35.1% with a university degree) than women giving birth in Canada.

In this specific pregnancy-based retrospective TTP study, socio-demographic and lifestyle data, as well as biospecimens collected during the first trimester of pregnancy (6 to \<14 weeks), from 1743 participants were analyzed. In MIREC, women were asked about the type of birth control they used before this pregnancy. If a method was indicated, women were then asked if they had stopped it before the pregnancy started or if there was a birth control failure. Women who answered that there was a birth control failure were excluded from the present analysis (Fig. [1](#DEU350F1){ref-type="fig"}). Sixteen patients who became pregnant with sperm donation, 3 with egg donation and 15 whose male partners required some infertility treatment were also excluded. Figure 1Participant\'s selection flow-chart.

The MIREC study was approved by the Research Ethics Board of Health Canada, the research ethics committee of the coordinating center of Ste-Justine\'s Hospital in Montreal, and the academic and hospital ethics committees of the 10 study sites across Canada. All the participants signed informed consent forms.

Study variables {#s2b}
---------------

### Time-to-pregnancy {#s2b1}

TTP was collected as a discrete variable (i.e. number of months of unprotected intercourse before conception) by this question: 'How long did it take you to get pregnant with this pregnancy?' (Number of months.)

Infertility was defined as having a TTP of more than 12 months or requiring infertility treatment for this pregnancy.

### PFOA, PFOS and PFHxS exposure {#s2b2}

Maternal blood samples collected during the first trimester of pregnancy were considered a surrogate of the preconception exposure to PFOS, PFOA and PFHxS. Maternal blood was collected in 10-ml sterile vacutainer tubes. Within 2 h of the blood draw, the samples were centrifuged and the plasma aliquoted into smaller cryovials to be stored at −80°C until analysis.

Chemical analyses were carried out by the toxicology laboratory of the Institut national de santé publique du Québec (INSPQ), <https://www.inspq.qc.ca/ctq/>, which is accredited by the Standards Council of Canada under ISO 17025 and CAN-P-43. The analytes were extracted at alkaline pH with methyl tertbutyl ether, and ion-pairing done with tetrabutylammonium hydrogensulfate, evaporated to dryness and dissolved in the mobile phase. Samples were analyzed with a Waters Acquity ultra performance liquid chromatography---tandem mass spectrometer (Milford, MA, USA) operated in the multiple reaction monitoring mode with an electrospray ion source in negative mode. The between-assay coefficients of variation for the assays were PFOS, PFOA and PFHxS were 3.6, 5.8 and 10%, respectively.

### Statistical analysis {#s2b3}

Descriptive statistics, including the percentage detected, medians and geometric means, were computed for all chemicals, and arithmetic means were found for important demographic variables. Concentrations below the limit of detection (LOD) were set to the LOD divided by 2. Each chemical concentration (ng/ml) was log-transformed to achieve normality and then divided by its SD so that the measure of effect could be interpreted per 1 − SD change in the log-transformed chemical concentration ([@DEU350C9]).

Fecundity odds ratios (FOR) were estimated using the Cox model, modified for discrete-time data ([@DEU350C2]). FORs estimate the odds of becoming pregnant each cycle, given exposure to the specific PFC, conditional on not being pregnant in the previous cycle. FORs \<1 denote reduction in fecundity or longer TTP, and FORs \>1 denote a shorter TTP. TTP was censored at the 13th month. The proportional hazard assumptions were verified for the discrete-time models ([@DEU350C2]). In addition, we used logistic regression to estimate the odds ratios (ORs) for infertility (TTP \> 12 months or infertility treatment). Statistical significance was assessed using an alpha level of 0.05.

Potential confounders included gestational age at blood draw (as an indicator of length of recall), maternal age, country of birth, education, household income, maternal and paternal smoking, and pre-pregnancy BMI. Maternal and paternal age were highly correlated (*r* = 0.73), which precluded inclusion of paternal age in the model. However, we conducted a sensitivity analysis by including the difference between paternal and maternal age as a covariate. Variables with a *P*-value of \<0.20 in the univariate analysis were potentially eligible for the multivariate model.

There is controversy on how to consider parity in the assessment of the toxicological effect of PFCs on TTP. Biologically, parity is influenced by a woman\'s fecundability. TTP is used as an epidemiological metric for the assessment of women\'s fecundability. Thus, we consider that conditioning (i.e. adjusting, stratifying, or restricting) on parity is redundant and would cause overadjustment, as parity is the result, among other factors, of proven fecundability. Based on the modern theory of diagrams for causal inference using Directed Acyclic Graphs (DAGs), as described in [@DEU350C28], we assume that E (exposure) is PFC, A is fecundability, S~1~ is the previous TTP, and that S~2~ is the current TTP (Fig. 1A in [@DEU350C28]). In a sense, S~1~ is a proxy for parity and for fecundability. Adjusting for it is like imperfectly adjusting for an intermediate, and could cause overadjustment bias ([@DEU350C41]). Furthermore, assuming that U~s~ is an unmeasured risk factor for the previous TTP (S~1~) and the current TTP (S~2~) (Fig. 1B in [@DEU350C28]), then S~1~ is a collider on a path from E to S~2~. Conditioning on a collider is susceptible to collider-stratification bias ([@DEU350C22]; [@DEU350C41]). It would open the blocked backdoor path between exposure and outcome ([@DEU350C28]).

In addition to DAGs, there is also toxicokinetic data to support the exclusion of parity in models for fecundity-related outcomes ([@DEU350C8]). PFCs are not lipophilic and while transfer during pregnancy and lactation has been reported in animal models ([@DEU350C34]) and humans ([@DEU350C21]; [@DEU350C3],[@DEU350C4]), the magnitude of change is minimal compared with lipophilic compounds. Moreover, daily exposure to PFCs via diet has been documented ([@DEU350C20]), supporting the continual exposure for women including pregnant women.

Statistical analysis was performed using STATA 10.0 (Stata Corporation, College Station, TX, USA) and SAS 9.3 (SAS Institute Inc., Cary, NC, USA), specifically for the discrete-time Cox proportional models.

Results {#s3}
=======

The cumulative probabilities of pregnancy for the cohort at months 1, 6 and 12 were 0.42 (95% confidence interval (CI) 0.40--0.45), 0.81 (95% CI 0.79--0.83) and 0.90 (95% CI 0.89--0.92), respectively. Socio-demographic characteristics of the population and their association with TTP are presented in Table [I](#DEU350TB1){ref-type="table"}. The mean maternal age was 32.8 (SD 5.0) years. About two-thirds of the women had a university degree, most were born in Canada, more than one-third reported a household income higher than \$100 000 CAD, half had at least one prior pregnancy with a live birth and about 15% were obese or active smokers during the preconception period. Women in the higher income categories were older and reported a higher proportion of infertility treatment for the index pregnancy. Maternal and paternal age, pre-pregnancy BMI and parity were associated with TTP. Maternal or paternal active smoking, gestational age at which the sample was collected, country of birth, household income and education were not associated with TTP. Table ICharacteristics of the study population and association with TTP: the Maternal-Infant Research on Environmental Chemicals (MIREC) study.Continuous variables*n*Mean (SD)^a^MedianMinimumMaximum*P* value\*\*Maternal age (years)174332.83 (4.96)32.7418.3446.35\<0.001Paternal age (years)151034.78 (5.68)34.5118.6658.74\<0.001Age difference (years)15101.80 (3.98)1.00−15260.18Gestational age (weeks)174112 (1.52)12.436140.19**Categorical variables*n*%TTP (months)Mean (SD)^a^Median (p25--p75)**Education Some college or less23613.55.8 (12.8)1 (1--5)0.46 College diploma39922.95.2 (8.9)2 (1--5) Undergraduate64437.05.7 (12.2)2 (1--5) Graduate (MSc PhD)46426.64.3 (6.4)2 (1--4)Country of birth Canada141281.05.3 (10.8)2 (1--5)0.93 USA271.54.7 (6.4)2 (1--6) Mexico80.55.1 (4.8)4.5 (1--9) China171.03.8 (4.8)1 (1--5) Other27916.05.1 (8.4)2 (1--6)Household income \<\$60 00036120.74.5 (10.1)2 (1--4)0.06 \$60 001--100 00060935.05.2 (9.9)2 (1--5) \>\$100 00069139.65.7 (10.7)2 (1--6) No response824.75.2 (10.9)2 (1--4)Parity conditional on gravidity No prior pregnancy50128.86.5 (13.7)2 (1--6)\<0.001 Prior pregnancy without live birth(s)27015.56.8 (12.1)2 (1--6) Prior pregnancy with live birth(s)97155.74.2 (7.2)2 (1--4)Maternal smoking Never107762.95.1 (8.9)2 (1--5)0.85 Former39222.55.3 (11.8)2 (1--5) Current^b^27215.65.7 (13.1)2 (1--4)Pre-pregnancy BMI (kg/m^2^) \<24.9103463.64.9 (9.6)2 (1--5)0.003 25--29.935521.95.2 (11.4)2 (1--4) \>3023614.56.7 (11.3)3 (1--7)Current paternal smoking No121783.05.2 (9.9)2 (1--5)0.83 Yes24917.05.6 (12.0)2 (1--5)[^1][^2][^3][^4]

Table [II](#DEU350TB2){ref-type="table"} presents the distribution of PFC concentrations in maternal plasma. PFOA, PFOS and PFHxS were detected in at least 95% of the samples. The geometric means (ng/ml) of PFOA, PFOS and PFHxS were 1.66 (95% CI 1.61--1.71), 4.59 (95% CI 4.46--4.72) and 1.01 (95% CI 0.97--1.05), respectively. Table IIPerfluoroalkyl acid levels (ng/ml) in maternal plasma (*n* = 1743).LOD*n* (%) \<LODMedianMinimumMaximumGM (95% CI)PFOA0.12 (0.12)1.7\<LOD161.66 (1.61--1.71)PFOS0.32 (0.12)4.7\<LOD364.59 (4.46--4.72)PFHxS0.269 (4.28)1\<LOD251.01 (0.97--1.05)[^5]

Crude FORs per one SD increase in log-transformed serum concentrations were significantly lower for PFOA 0.91 (95% CI 0.86--0.96) and PFHxS 0.94 (95% CI 0.89--1.00), while there was no statistically significant association with PFOS 0.97 (95% CI 0.92--1.03) (Table [III](#DEU350TB3){ref-type="table"}). Fecundability decreased by 4% per 1 year increase in maternal age (FOR = 0.96; 95% CI 0.95--0.97). Obesity (BMI \>30 kg/m^2^) was associated with a 25% reduction in fecundability (FOR = 0.75; CI 95% 0.63--0.90), and annual household income \>\$100 000 CAD with a 21% decrease (FOR = 0.79; CI 95% 0.67--0.93). Education and smoking status were not associated with fecundability reduction. Table IIICrude fecundity odds ratios (FOR) for TTP.*n*Crude FORs95% CI*P* value^b^PFOA^a^, ng/ml17430.910.86--0.960.001PFOS^a^, ng/ml17430.970.92--1.030.33PFHxS^a^, ng/ml17430.940.89--1.00^c^0.04Age17430.960.95--0.97\<0.001Gestational age17430.980.94--1.010.18Pre-pregnancy BMI (kg/m^2^)0.04 \<24.910341 25--29.93551.030.89--1.20 \>302360.750.63--0.90Education0.68 Graduate (MSc PhD)4641 Undergraduate6440.950.82--1.10 College diploma3990.910.77--1.08 Some college or less2360.970.82--1.21Household income \<60 00036110.04 60 000--100 0006090.860.73--1.01 \>100 0006910.790.67--0.93 No response820.890.65--1.20Maternal smoking0.63 Never10771 Former3921.050.91--1.21 Current^d^2721.080.91--1.27Current paternal smoking0.68 No12171 Yes2491.050.91--1.21[^6][^7][^8][^9][^10]

In models adjusted for maternal age and BMI, PFOA and PFHxS were associated with an 11% (FOR = 0.89; 95% CI 0.83--0.94) and 9% (FOR = 0.91; 95% CI 0.86--0.97) reduction in fecundability per one SD increase in log-transformed serum concentrations, respectively; no significant association was observed for PFOS (FOR = 0.96; 95% CI 0.91--1.02) (Table [IV](#DEU350TB4){ref-type="table"}). When added to the model with the other variables, household income was no longer significant. Table IVAdjusted FORs for TTP (*n* = 1625)^a^.Adjusted FORs95% CI*P* value^b^PFOA (ng/ml)0.890.83--0.94**\<0**.**001**Age0.960.94--0.97\<0.001Pre-pregnancy BMI (kg/m^2^)0.001 \<24.91 25--29.91.030.89--1.20 \>300.710.60--0.86PFOS (ng/ml)0.960.91--1.02**0**.**17**Age0.960.95--0.97\<0.001Pre-pregnancy BMI (kg/m^2^)\<0.001 \<24.91 25--29.91.030.89--1.20 \>300.720.60--0.86PFHxS (ng/ml)0.910.86--0.97**0**.**002**Age0.960.94--0.97\<0.001Pre-pregnancy BMI (kg/m^2^)\<0.001 \<24.91 25--29.91.050.90--1.22 \>300.730.61--0.87[^11][^12][^13][^14]

The adjusted odds of infertility (TTP \> 12 months or infertility treatment to become pregnant) increased by 31% per one SD increase of PFOA (OR = 1.31; 95% CI 1.11--1.53) and by 27% per one SD increase of PFHxS (OR = 1.27; 95% CI 1.09--1.48). No significant association was observed between concentrations of PFOS and the odds of infertility (odds ratio (OR) = 1.14; 95% CI 0.98--1.34) (Table [V](#DEU350TB5){ref-type="table"}). Table VAdjusted odd ratios for infertility (*n* = 1625)^a^.Odds ratios95% CI*P* valuePFOA (ng/ml)1.311.11--1.530.001PFOS (ng/ml)1.140.98--1.340.09PFHxS (ng/ml)1.271.09--1.480.003[^15][^16][^17]

Including the difference between paternal and maternal age resulted in very similar results for all the models presented. However, due to missing information on paternal age, the sample is reduced from 1625 to 1419 women. For this reason, our final models did not include the age difference, a variable that was also not significant in the univariate analysis (Table [I](#DEU350TB1){ref-type="table"}).

Discussion {#s4}
==========

The MIREC study is the largest cohort of pregnant women to date measuring the concentrations of PFOA, PFOS and PFHxS in plasma samples collected during the first trimester of pregnancy. The participation rate of 39% in the MIREC study is consistent with participation rates of several large prospective cohort studies. There is evidence from similar pregnancy cohorts that this level of participation does not increase the risk of bias ([@DEU350C36]). The time-frame of the study, from 2008 to 2011, reflects current levels of exposure to these chemicals, especially after the move to reduce and phase out several PFCs over the last decade. We observed that increased concentrations of PFOA and PFHxS were associated with decreased fecundability as measured by a longer TTP, and increased odds of infertility, even at lower levels of exposure than previously documented. The median concentrations in our participants (1.7 ng/ml for PFOA, and 4.7 ng/ml for PFOS) were lower than those reported for women in the Danish National Birth Cohort conducted between 1996 and 2002 (5.3 ng/ml for PFOA and 33.7 ng/ml for PFOS) ([@DEU350C18]), the Norwegian Mother and Child Cohort Study conducted between 2003 and 2004 (2.2 ng/ml for PFOA and 13.0 ng/ml for PFOS) ([@DEU350C49]), and a Danish study conducted among trade union workers between 1992 and 1995 (5.6 ng/ml for PFOA and 36.3 ng/ml for PFOS) ([@DEU350C46]). Also, our geometric mean concentrations (1.66 ng/ml; 95% CI 1.61--1.71 for PFOA and 4.59 ng/ml; 95% CI 4.46--4.72 for PFOS) were lower than those reported in the LIFE study conducted in Texas and Michigan between 2005 and 2007 (3.11 ng/ml; 95% CI 2.91--3.33 for PFOA and 11.76 ng/ml; 95% CI 11.01--12.57 for PFOS) ([@DEU350C9]).

Two previous studies have evaluated the effect of PFOA and PFOS on TTP using a retrospective pregnancy TTP design. Our results are in agreement with those on PFOA reported by [@DEU350C18] in a subset of 1400 women randomly selected from the Danish National Birth Cohort; however, we did not find an association between TTP and PFOS, which might be explained by the differences in exposure. Indeed, while our median PFOA level was 1/3 of those reported by [@DEU350C18], our median PFOS was 1/14 their level. The covariates included in our models were similar, except for the consideration of parity as a confounder by [@DEU350C18].

A second study, a case--control analysis within the Norwegian Mother and Child Cohort, reported an increased odds of subfecundity (TTP \> 12 months) with elevated PFOA and PFOS levels in a model (not adjusted for parity) ([@DEU350C49]). A recent analysis of the MoBa cohort, using the discrete-time Cox proportional hazard model, also reported diminished fecundability at increasing concentrations of PFOA (FOR 0.83; 95% CI 0.75--0.91) ([@DEU350C15]). In the study by [@DEU350C49], however, the authors considered that reverse causation could account for their reported association in parous women ([@DEU350C39]). Thus, women with longer TTP would have higher PFCs levels due to only a longer time since their previous pregnancy, allowing re-accumulation of the PFCs that had decreased during pregnancy and post-partum through placenta transfer and breastfeeding. Based on this assumption, they reported their final conclusion according to a second model, stratifying by parity. In this model, the ORs for subfecundity were elevated only among parous women, which, according to the authors, support the reverse causation hypothesis ([@DEU350C49]). However, these results were not replicated by [@DEU350C19] after stratification by parity, where stronger associations were reported for PFOS and PFOA in nulliparous women, and for PFOA in the case of multiparous women, thus refuting reverse causation.

In agreement with other authors, we considered that neither adjustment nor stratification for parity should be conducted when studying the reproductive adverse effects of PFCs, as this will introduce overadjustment through collider-stratification bias ([@DEU350C22]; [@DEU350C41]; [@DEU350C40]). To describe this type of bias, [@DEU350C22] used the example of the effect of exposure to an unopposed estrogen therapy (E) and endometrial cancer (D), stratifying (conditioning) on uterine bleeding (C). It was common practice to assess the effect of estrogen therapy on endometrial cancer only among women presenting with uterine bleeding, as a marker of estrogen use and cancer. However, it was demonstrated that the measure of effect among these women would be much smaller than the true causal association because of the strong effects of both the therapy and the cancer on bleeding risk, and therefore, the bias induced by stratification on bleeding was toward the null ([@DEU350C22]). The same bias would be introduced if the association of PFCs (E) and TTP (D) were conditioned on parity (C).

Besides collider-stratification bias, there are also toxicokinetic data to support the exclusion of parity in our models ([@DEU350C8]). Compared with lipophilic compounds, the magnitude of changes for PFCs during pregnancy and lactation appear minimal, as indicated by the relatively small changes in maternal serum concentrations during pregnancy or through 6 months post-partum reported in a pregnancy cohort study ([@DEU350C21]). In addition, PFCs have the capacity to bind to serum albumin ([@DEU350C23]), which may account for breast milk concentrations being ∼1000 times lower than blood concentrations ([@DEU350C21]; [@DEU350C30]). Furthermore, independently of parity, women are continuously exposed to PFCs, not only due to the long half-lives of these chemicals, but also through an estimated daily uptake of 2--3 ng/kg of PFOS and PFOA, with 90% coming from dietary sources ([@DEU350C20]).

In addition, we included women in our study who had had fertility treatment for the index pregnancy, i.e. 7.3% of the study population, as was also done by [@DEU350C18]. In our descriptive phase of analysis, we found that the geometric mean levels of PFOA and PFHxS were significantly higher in participants receiving fertility treatment for the index pregnancy than those of untreated participants, and this was maintained after age-adjustment (data not shown). We also noted that half of these patients reported a TTP \< 12 months, even if these treatments (i.e. ovulation induction, intrauterine insemination and IVF) are rarely prescribed before 12 months of attempting pregnancy. Our hypothesis is that some of the women reported their TTP as the number of months since their first cycle of fertility treatment until the successful cycle, some considered the number of months of trying before starting fertility treatment, and others counted both. Moreover, if they had used fertility treatment for a previous pregnancy and therefore were able to access it for this pregnancy without having to wait during 12 months of trying, the reported TTP would probably be \<12 months. In [@DEU350C49] cases were randomly selected from women who reported a TTP \> 12 months but not according to fertility treatment, likely leading to the exclusion of some potential cases that received fertility treatment but reported a TTP \< 12 months.

Two additional studies have addressed the association between PFCs and TTP using a prospective couple-based cohort design. In a survey conducted among trade union workers in Denmark from 1992 to 1995, no consistent pattern was observed between TTP and eight PFCs, including PFOA, PFOS, PFHxS and PFOSA, measured in the serum of 222 women attempting pregnancy for the first time, followed for up to six cycles of trying ([@DEU350C46]). More recently, [@DEU350C9] reported the results from the LIFE study, including biomonitoring data from 501 couples followed for upto 12 months of attempting during 2005 and 2007. Decreased fecundability was observed at higher concentrations of PFOSA in females in the adjusted model; however, no association was found for the other 6 PFCs assessed, including PFOA and PFOS in their unadjusted analysis. PFOSA was not measured in the MIREC study. Detection of this chemical is currently very low in the USA ([@DEU350C11]) due to its phasing-out since 2002 ([@DEU350C1]). In fact, PFOSA was not detected in 90% of the samples from the LIFE study ([@DEU350C9]).

Some methodological aspects of our study need to be considered. First, in pregnancy-based TTP, infertile couples who do not opt for fertility treatment or have no access to it and those whose fertility treatment is unsuccessful are excluded from the study, resulting in the systematic underrepresentation of infertile women and the selection of a healthier population ([@DEU350C29]). Nonetheless, pregnancy-based TTP studies have been successful in identifying environmental exposures that may adversely affect fertility, as it is expected that at current levels of exposure, the toxic effect of these contaminants do not lead to complete infertility ([@DEU350C48]). Secondly, TTP was assessed at a mean gestational age of 12 weeks (SD 1.52) in MIREC, similar to the gestational age at which TTP was assessed by [@DEU350C18], but earlier than in [@DEU350C49], which was at ∼17 weeks of gestation. Studies that have assessed the validity of this recall have reported reasonable validity if collected in the short-term ([@DEU350C50]; [@DEU350C13]). Thirdly, we used the first trimester concentration of PFCs as a surrogate of the preconception exposure. Since the half-lives of these chemicals are considerably long ([@DEU350C38]) and they are persistent in the environment, we considered that these concentrations reflected those at the time of the pregnancy attempts. In addition, one recent study reported robust correlations between two subsequent measures of PFCs in blood samples of 53 men collected 6 years apart, in 2001 and 2007 (Spearman\'s *ρ* = 0.75 for PFOA and 0.81 for PFOS, and PFHxS) ([@DEU350C37]).

One limitation of our study is that we do not have information on male partner exposure to PFCs. The LIFE study is the only study that has measured concentrations of PFCs in both partners ([@DEU350C9]), reporting high correlations between partner concentrations. Since TTP is an epidemiological metric of couple fecundity, we are unable to determine whether the effects are female, male or both. Furthermore, we did not assess specific end-points of fecundability such as menstrual cycle characteristics, markers of ovulation or semen quality ([@DEU350C10]).

With regard to the biological mechanism of action, there are limited toxicological studies assessing the effect of PFCs on reproductive outcomes. *In vitro*, some PFCs have the potential to affect estrogen-receptor and androgen-receptor transactivity ([@DEU350C31]). In rats, exposure to PFOS has shown estrous cyclicity disruption and neurotransmitter imbalance ([@DEU350C6]). Thyroid dysfunction could also be an endocrine target for PFCs, with some evidence from animal ([@DEU350C32]; [@DEU350C44]; [@DEU350C35]; [@DEU350C12]) and human studies ([@DEU350C14]; [@DEU350C47]) showing decreased levels of some thyroid hormones at higher concentrations of exposure. Although these studies suggest a possible endocrine-disrupting effect, additional studies need to be assessed to support an effect and its mechanistic pathway. Recently, PFOA and perfluorononanoic acid (PFNA) were reported to be associated with endometriosis in a cohort of 495 women undergoing laparoscopy/laparotomy in the ENDO study (Endometriosis---Natural History, Diagnosis and Outcomes Study) ([@DEU350C8]). Endometriosis is a condition associated with impaired fecundability. Therefore, endometriosis or its determinants could be on the etiologic or causal pathways of the association between PFCs and TTP.

In conclusion, our results add to the evidence that exposure to PFOA and PFHxS, even at lower levels than previously reported, may reduce fecundability, as measured by a longer TTP and increased odds of infertility (TTP \> 12 months). Future research should focus on the mechanisms involved in this potential endocrine-disrupting effect. Methodological differences in the causal models of previous studies have impaired possible conclusions about the potential adverse effect of PFCs and TTP.
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[^1]: BMI, body mass index.

[^2]: ^a^Arithmetic mean and SD.

[^3]: ^b^Women who stopped during pregnancy or 1 year before.

[^4]: \*\**P*-values for the association with TTP: likelihood ratio for continuous variables, log-rank test for categorical variables.

[^5]: LOD, limit of detection; GM, geometric mean; CI, confidence interval; PFOA, perflurooctanoic acid; PFOS, perfluorooctane sulfonate; PFHxS, perfluorohexane sulfonate.

[^6]: PFOA, perflurooctanoic acid; PFOS, perfluorooctane sulfonate; PFHxS, perfluorohexane sulfonate.

[^7]: ^a^Chemical plasma concentrations were log-transformed and divided by their SDs.

[^8]: ^b^Wald PHREG procedure.

[^9]: ^c^After rounding.

[^10]: ^d^Those who quit during pregnancy or \<1 year prior to the study visit.

[^11]: Chemical plasma concentrations were log-transformed and divided by their SDs.

[^12]: PFOA, perflurooctanoic acid; PFOS, perfluorooctane sulfonate; PFHxS, perfluorohexane sulfonate.

[^13]: ^a^1625 women (118 missing values for pre-pregnancy weight).

[^14]: ^b^Wald *χ*^2^ test PHREG procedure.

[^15]: Chemical plasma concentrations were log-transformed and divided by their SDs.

[^16]: PFOA, perflurooctanoic acid; PFOS, perfluorooctane sulfonate; PFHxS, perfluorohexane sulfonate.

[^17]: ^a^1625 women (118 missing values for pre-pregnancy weight).
